Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 6/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 5/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 0.76 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.76 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.76 |
| ▸ | GAA | P10253 | 1/20 | 0.76 |
| ▸ | HTT | P42858 | 1/20 | 0.76 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.76 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.76 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.76 |
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | TP53 | P04637 | 1/20 | 0.76 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.75 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gr-79236 SCHEMBL9791896 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2BCYP2D6 | |
| Gr-79236 SCHEMBL472413 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2BCYP2D6 | |
| Gr-79236 SCHEMBL22452097 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2BCYP2D6 | |
| Gr-79236 SCHEMBL24437080 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2BCYP2D6 | |
| Gr-79236 SCHEMBL2779193 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2BCYP2D6 | |
| Gr-79236 SCHEMBL24437079 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2BCYP2D6 | |
| Gr-79236 SCHEMBL12355491 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2BCYP2D6 | |
| Gr-79236 SCHEMBL24436934 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2BCYP2D6 | |
| Gr-79236 SCHEMBL21033425 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2BCYP2D6 | |
| Gr-79236 SCHEMBL1101275 | 1.00 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2BCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2704793-B1 | REGULATION OF AMYLOID BETA MOLECULAR COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIV RAMOT (IL) | 2019-07-17 | — | — | EP | claimed |
| US-9192670-B2 | Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2015-11-24 | — | — | US | claimed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY INC (US) | 2022-02-10 | — | — | US | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2021-05-13 | — | — | US | disclosed |
| US-20200397907-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | OTONOMY, INC. | 2020-12-24 | — | — | US | disclosed |
| US-10821185-B2 | Triglyceride otic formulations and uses thereof | OTONOMY INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20180000950-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | OTONOMY, INC. | 2018-01-04 | — | — | US | disclosed |
| US-20160095902-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTONOMY, INC. | 2016-04-07 | — | — | US | disclosed |
| US-9192670-B2 | Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2015-11-24 | — | — | US | disclosed |
| US-9132087-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140241990-A1 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | TUFTS UNIVERSITY (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013049725-A2 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | TUFTS UNIVERSITY (US) | 2013-04-04 | — | — | WO | disclosed |
| US-20120277199-A1 | Modulation of Gel Temperature of Poloxamer-Containing Formulations | OTONOMY, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| WO-2011050206-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SINONASAL DISORDERS | OTONOMY, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. (US) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000950-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | ADORA3 2382/4885ADORA1 2143/4885ADORA2A 2246/4885 |
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | ADORA3 2478/4885ADORA1 2255/4885ADORA2A 2398/4885 |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | ADORA3 84/4885ADORA1 9/4885ADORA2A 24/4885 |
| US-20140241990-A1 | METHODS OF USING ADENOSINE A1 RECEPTOR ACTIVATION FOR TREATING DEPRESSION | ADORA2A, ADORA1, ADORA3 | ADORA3 3/4885ADORA1 2/4885ADORA2A 1/4885 |
| US-10821185-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | ADORA3 2382/4885ADORA1 2143/4885ADORA2A 2246/4885 |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | ADORA3 84/4885ADORA1 9/4885ADORA2A 24/4885 |
| US-20160095902-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTC, AQP4, SLC26A4 | ADORA3 84/4885ADORA1 9/4885ADORA2A 24/4885 |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTC, AQP4, SLC26A4 | ADORA3 84/4885ADORA1 9/4885ADORA2A 24/4885 |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | ADORA3 2478/4885ADORA1 2255/4885ADORA2A 2398/4885 |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | ADORA3 84/4885ADORA1 9/4885ADORA2A 24/4885 |
| US-20120277199-A1 | Modulation of Gel Temperature of Poloxamer-Containing Formulations | PTGIR, HSPH1, HSP90AA1 | ADORA3 3154/4885ADORA1 2686/4885ADORA2A 1279/4885 |
| US-20200397907-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | ADORA3 2382/4885ADORA1 2143/4885ADORA2A 2246/4885 |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | ADORA3 84/4885ADORA1 9/4885ADORA2A 24/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | ADORA3 84/4885ADORA1 9/4885ADORA2A 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.